

Acorai is transforming the detection and management of heart failure through non-invasive pulmonary and cardiac pressure-sensing



FDA Breakthrough
Device designated
US & EU regulatory
approvals expected in
2026/2027

\$17M

\$13M invested to date
\$4M in grants awarded

2000

Patients enrolled across 20
hospitals, 50% US patients
Currently demonstrating
accuracies superior to existing
standard-of-care tools

3

Patents granted
7 patents filed
Proprietary datasets
collected over 5 years

Acorai is raising \$4.5M to obtain US & EU regulatory approvals in 2026/2027

Non-invasive cardiac and pulmonary pressure sensing to improve decision-making, reduce readmissions, cost of care and improve quality of life



The Acorai device **estimates the right atrial- and pulmonary capillary wedge pressures** to help identify congestion and personalize heart failure care

The device records data for 5 minutes, and results are presented on the display

End user-driven application of Generative Artificial Intelligence models in healthcare (GenAI4EU)

Acorai can support in the outcomes:

- safer, more efficient and personalised care
- Enhanced outcomes, personalized care
- Cost savings

Leveraging multimodal data to advance Generative Artificial Intelligence applicability in biomedical research (GenAI4EU)

Acorai can support in e.g.:

- Use of our multimodal technology
- Leverage of machine learning models

Medical technology

Acorai is a MedTech company with initial focus on heart failure management

SAVE Sensor System

Acorai's multimodal sensor system includes SCG, PCG, PPG and ECG

Machine Learning

Proprietary datasets trained on over 2000+ patients in clinical trials

Experience from EU projects

Acorai has been project leader for and involved in projects: EIC accelerator, Eurostars, Eureka, EIT Health etc.

Contact info Acorai

Filip Peters (CEO):

filip.peters@acorai.com

Kasper Bourdette (COO):

kasper.bourdette@acorai.com

Dan Vikström (Finance Manager)

dan.vikstrom@acorai.com

